The cost of SGLT2 inhibitors, the cost of hospitalization for heart failure, the cost of standard therapy, and baseline risks of all-cause death and hospitalization for heart failure were the most critical factors for the cost-effectiveness of the medication. Here, SLC5A2 is linked to heart failure.